Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patent challenger Natco is now Gilead licensee for Sovaldi

This article was originally published in Scrip

Executive Summary

Patent challenger Natco Pharma has made a strategic about turn and has now emerged as a licensee for Gilead Sciences's blockbuster hepatitis C therapy, Sovaldi (sofosbuvir).

You may also be interested in...



Natco CEO On Dynamics In The HCV Market

Nexavar compulsory license holder Natco Pharma is counted among the leading players in the Indian oncology market and now looks to be aiming for an encore in the hepatitis C segment. Natco vice chair and CEO Rajeev Nannapaneni talks to Scrip of the large patient numbers on HCV therapy and outlines a potential market "split" in certain rest of the world (RoW) territories with the arrival of Gilead's Epclusa.

India Keeps Door Ajar For Hydroxychloroquine Exports, Drug Makers Geared Up

Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.

Amid Aborted Sandoz Deal, A Silver Lining For Aurobindo?

The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.

Topics

Related Companies

UsernamePublicRestriction

Register

SC027965

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel